申请人:Atrin Pharmaceuticals LLC
公开号:US20170291911A1
公开(公告)日:2017-10-12
The disclosure is directed to compounds and compositions that inhibit Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase and methods of their use.
该披露涉及抑制共济失调毛细血管扩张性和Rad3相关蛋白激酶(ATR)的化合物和组合物,以及它们的使用方法。